Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

Prof. Jukema explains the mechanism of epigenetics and how the BET inhibitor apabetalone can potentially impact CVD. In addition, he presents findings of first clinical studies with apabetalone.

Prof. Libby discusses the inflammatory residual risk in diabetes patients and explains how epigenetic modulation of (inflammatory) gene transcription can potentially reduce CV risk.